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Background: The α7 nicotinic acetylcholine receptor (nAChR) is an important molecular target in neuropsychiatry
and oncology. Development of applicable highly specific radiotracers has been challenging due to comparably low
protein expression. To identify novel ligands as candidates for positron emission tomography (PET), a library of
diazabicyclononane compounds was screened regarding affinity and specificity towards α7 nAChRs. From these,
[18F]NS14490 has been shown to yield reliable results in organ distribution studies; however, the radiosynthesis of
[18F]NS14490 required optimization and automation to obtain the radiotracer in quantities allowing dynamic PET
studies in piglets.
Methods: Automated radiosynthesis of [18F]NS14490 has been performed by [18F]fluorination with the tosylate
precursor in the TRACERlab™ FX F-N synthesis module (Waukesha, WI, USA). After optimization, the radiochemical
yield of [18F]NS14490 was consistently approximately 35%, and the total synthesis time was about 90 min. The
radiotracer was prepared with >92% radiochemical purity, and the specific activity at the end of the synthesis was
226 ± 68 GBq μmol−1. PET measurements were performed in young pigs to investigate the metabolic stability and
cerebral binding of [18F]NS14490 without and with administration of the α7 nAChR partial agonist NS6740 in
baseline and blocking conditions.
Results: The total distribution volume relative to the metabolite-corrected arterial input was 3.5 to 4.0 mL g−1
throughout the telencephalon and was reduced to 2.6 mL g−1 in animals treated with NS6740. Assuming complete
blockade, this displacement indicated a binding potential (BPND) of approximately 0.5 in the brain of living pigs. In
addition, evidence for specific binding in major brain arteries has been obtained.
Conclusion: [18F]NS14490 is not only comparable to other preclinically investigated PET radiotracers for imaging of
α7 nAChR in brain but also could be a potential PET radiotracer for imaging of α7 nAChR in vulnerable plaques of
diseased vessels.
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The homomeric α7 nicotinic acetylcholine receptor (α7
nAChR), together with the heteromeric α4β2 nAChR,
belongs to the cysteine-loop family of ligand-gated ion
channels and they represent the two most abundant
nAChR populations in the brain [1]. The α7 nAChRs are
expressed in all cell types present in the brain, including
cortical neurons [2], astrocytes [3], microglia [4,5], oligo-
dendrocyte precursor cells [6] and endothelial cells [7].
They are implicated in inflammatory processes related to
neurodegeneration, psychiatric diseases and brain trauma
[8,9]. Furthermore, neuronal and non-neuronal expression
of the α7 nAChR has also been found in peripheral organs
[6,10], and the receptors were proposed to be involved in
the development of cancer [8,11]. Recently, studies indi-
cate an important role for α7 nAChRs in cardiac angio-
genesis [12] and in modulation of heart rate dynamics
during systemic inflammation [13].
Given the wide distribution and diverse functions of
the α7 nAChR, quantitative molecular imaging offers the
possibility to improve diagnostics in major fields of nu-
clear medicine such as oncology, neurology and cardi-
ology. As recently reviewed [14,15], considerable efforts
to develop α7 radioligands suitable for positron emission
tomography (PET) imaging have been made in the last
decade. This goal is challenging due to the comparably
low protein expression under physiological conditions.
By use of [11C]CHIBA-1001, the only α7-specific PET
radiotracer tested in humans so far, only small regional
binding differences of uncertain pharmacological specifi-
city were detectable in the brain [16]. Furthermore, the
regional distribution of [11C]CHIBA-1001 did not match
that of the highly selective α7 nAChR radiotracer
[125I]α-bungarotoxin in monkey and human brain sam-
ples [17] which corresponds to the low affinity and se-
lectivity of [3H]CHIBA-1001 in rodent brain [18]. Very
recently, [18F]ASEM has shown promising properties for
the quantitative imaging of α7 nAChR in the brain of
non-human primates [19]. Up to that, the 1,4-diazabicyclo
[3.2.2]nonane derivatives [11C]NS14492 [20], [18F]NS10743
[21] and [18F]NS14490 [22], all based on compounds de-
veloped by NeuroSearch A/S (Ballerup, Denmark) [23,24],
were the most qualified promising radiotracers for im-
aging of α7 nAChR by PET. Of these, [11C]NS14492 and
[18F]NS10743 were assessed by preclinical PET studies in
pigs [20,25]. Although the general suitability has been
shown, the magnitude of the binding potential (BPND; ap-
proximately 0.5) was at the lower limit for an applicable
PET radiotracer. Binding of the higher affine [18F]
NS14490 [22] in mouse brain slices correlated with the
pattern of α7 nAChR expression and was displaced with
the α7 nAChR-specific alkaloid methyllycaconitine [8].
Furthermore, brain uptake and target specificity were
proven by organ distribution studies in mice [22].Therefore, to investigate if higher affinity of [18F]NS14490
in vitro translates into higher binding potential in vivo, the
radiosynthesis of [18F]NS14490 was optimized and auto-
mated to obtain the radiotracer in quantities allowing dy-
namic PET studies in piglets. Furthermore, to prove the
hypothesis that [18F]NS14490 specifically binds to α7
nAChR expressed in the brain and cerebral vasculature of
piglets, blocking studies by administration of the α7
nAChR partial agonist NS6740 were performed.
Methods
Animals and drugs
Animal experimental procedures were approved by the
Animal Care and Use Committee of Saxony (TVV 22/10).
Six female German Landrace pigs (mean weight 15.8 ±
0.8 kg, mean age 8 weeks) were used in this study. Anaes-
thesia and surgery of the animals were performed as de-
scribed previously [26].
Reagents and solvents of highest available quality were
obtained from Merck KGaA (Darmstadt, Germany),
Sigma-Aldrich Co. LLC. (Taufkirchen, Germany), Carl
Roth GmbH + Co KG (Karlsruhe, Germany), VWR Inter-
national GmbH (Darmstadt, Germany) and Fischer Sci-
entific GmbH (Schwerte, Germany). Chemicals and
solvents were used without further purification. The ref-
erence compound NS14490 (1-(2-fluoroethyl)-6-(5-(1,4-
diazabicyclo[3.2.2]nonan-4-yl)-1,3,4-oxadiazol-2-yl)indole)
and the blocking compound NS6740 (1,4-diazabicyclo
[3.2.2]nonan-4-yl(5-(3-(trifluoromethyl)phenyl)furan-2-yl)
methanone; also known as A-793394) was obtained from
DanPET AB (Malmö, Sweden) [27].
Radiochemistry and analytics
No-carrier-added [18F]fluoride was obtained from a cyclo-
tron Cyclone®18/9 (iba International, Louvain-la-Neuve,
Belgium) by irradiation of [18O]H2O in a Nirta® [
18F]fluor-
ide L target with a fixed energy proton beam (18 MeV).
[18O]H2O (Hyox 18 enriched water) was purchased from
Rotem Industries Ltd. (Arava, Israel)/Rotem GmbH
(Leipzig, Germany) or [18O]H2O recycled by the in-house
established method [28] was used. Radiosyntheses were
performed on a TRACERlab™ FX F-N synthesizer from
GE Healthcare (Waukesha, WI, USA) equipped with PU-
1580 pump from Jasco International Co. (Gross-Umstadt,
Germany), a WellChrom K-2001 UV detector from
KNAUER GmbH (Berlin, Germany, a NaI(Tl)-counter
and an automated data acquisition tool (NINA software
version 4.8 rev. 4, Nuclear Interface GmbH, Dortmund,
Germany).
Radio-thin layer chromatography (radio-TLC) analyses
were accomplished with Polygram® ALOX N/UV254
plates (Macherey-Nagel, Düren, Germany) using methy-
lene chloride/methanol 95:5 (radiosynthesis) and 90:10
(metabolite analysis). The reference spots were visualized
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analysed with a phosphor imager BAS-1800II (Fuji Film,
Tokyo, Japan) and evaluated with AIDA 2.31 software
(raytest Isotopenmessgeräte GmbH, Straubenhardt,
Germany). Labelling yields were calculated as percent-
ages of the product peak relative to the total activity
detected.
For analytical radio-high performance liquid chromato-
graphy (radio-HPLC), two devices from Jasco International
Co. were used (pumps: PU-2080Plus, quaternary gradient:
LG-2080-045 and ternary gradient LG-2080-02S, 4-line
degasser DG-2080-54 and 3-line degasser DG-2080-53,
autosamplers AD-2055Plus, UV/vis detectors UV-2075
Plus, coupled with radioactivity flow monitors for HPLC
Gabi Star (raytest Isotopenmessgeräte GmbH)). The co-
lumns used for analytical radio-HPLC were Multospher®
120 RP18-AQ 250 mm× 4.6 mm, 5 μm (CS-Chromatogra-
phie Service GmbH, Langerwehe, Germany), one device
equipped with precolumn Multospher® 120 RP18-AQ
40 mm× 4.6 mm, 5 μm (CS-Chromatographie Service
GmbH). We used a previously calibrated Wallac 1480
WIZARD 3″ system (PerkinElmer LAS GmbH, Rodgau,
Germany) for γ-quantification; radio-HPLC data were cor-
rected for decay and background.
Semi-preparative separations were performed with the
following reverse phase columns: Multospher® 120 RP-
18 AQ, 5 μm (CS-Chromatographie Service); Reprosil-
Pur® C18-AQ, 7 μm; and Reprosil-Gold® 120 C18, 10 μm
(Dr. Maisch HPLC GmbH, Ammerbuch-Entringen,
Germany), 50 mm × 10 mm (precolumn) and 150 mm ×
10 mm. Mobile phase flow rates and compositions are
described in captions of the relevant figures. Chromafix®
30 PS-HCO3
− solid-phase extraction (SPE) cartridges
(Macherey-Nagel GmbH) were used for the separation
of [18F]fluoride from irradiated water, and Chromafix®
HR-X, 85 μm (polystyrene/divinylbenzene) cartridges
conditioned with 5 mL desorption agent and distilled
water were used for product purification after semi-
preparative HPLC.
The tosylate precursor 1 was synthesized as described
recently [22]. Automated radiosynthesis of [18F]NS14490
has been developed, and in vitro autoradiography of pig-
let brain has been performed as described in detail in
Additional file 1.
PET measurement
The PET scans were run in six female juvenile pigs
under isoflurane anaesthesia using [18F]NS14490. Anaes-
thesia and surgery of the animals were performed as de-
scribed previously [26]. In brief, the animals were
premedicated with midazolam (1 mg kg−1 i.m.) followed
by induction of anaesthesia with 3% isoflurane in 70%
N2O/30% O2. All incision sites were infiltrated with 1%
lidocaine, and anaesthesia was maintained throughoutthe surgical procedure with 1.5% isoflurane. A central
venous catheter was introduced through the left external
jugular vein and used for the administration of the ra-
diotracer and drugs, and for volume substitution with
heparinized (50 IE mL−1) lactated Ringer's solution
(2 mL kg−1 h−1). An endotracheal tube was inserted by
tracheotomy for artificial ventilation (Servo Ventilator
900C, Siemens-Elema, Solna, Sweden) after immobiliza-
tion with pancuronium bromide (0.2 mg kg−1 h−1). The
artificial ventilation was adjusted to maintain normoxia
and normocapnia (Radiometer ABL 500, Copenhagen,
Denmark). Polyurethane catheters (Ø 0.5 mm) were ad-
vanced through the left and the right femoral arteries into
the abdominal aorta to withdraw arterial blood samples
for regular monitoring of blood gases and for radiotracer
input function measurements. Body temperature was
monitored by a rectal temperature probe and maintained
at approximately 38°C by a heating pad. After completion
of surgery, anaesthesia was maintained with 0.5% isoflur-
ane in 70% N2O/30% O2, and the animals were allowed to
stabilize for 1 hour before PET measurement.
PET imaging was performed according to the protocol
described recently [25]. Briefly, the animals were scanned
in prone position with the head held in the aperture of a
clinical tomograph (ECAT EXACT HR+, CTI/Siemens,
Knoxville, TN, USA) using a custom-made head holder.
For attenuation and scatter correction, transmission scans
were acquired using three rotating 68Ge/68Ga rod sources.
[18F]NS14490 (520 ± 150 MBq; SA: 110 ± 47 GBq μmol
–1)
was applied in 10 mL saline as a 2-min i.v. infusion using
by a syringe pump, followed by flushing with 10 mL hepa-
rinized saline (50 IE mL−1). The emission scan started
upon the initiation of the injection, and dynamic emission
data were acquired for a total of 240 min. Three animals
were investigated under baseline conditions, and another
three under blocking conditions with administration of
3 mg kg−1 i.v. of the α7 nAChR partial agonist/functional
antagonist NS6740 (DanPET AB) at 3 min before radio-
tracer injection. A continuous infusion of 1 mg kg−1 h−1
NS6740 was applied throughout the scan.
Arterial blood was sampled continuously using a peri-
staltic pump during the first 20 min of the recording,
followed by manual sampling at 25, 30, 40, 50, 60, 90,
and 120 min after injection. After centrifugation, the
total plasma radioactivity concentration was measured
using a γ-counter (1470 Wizard, PerkinElmer, Shelton,
CT, USA) cross-calibrated to the PET scanner. Addition-
ally, arterial whole blood was sampled manually at 4, 16,
30, 60, and 120 min p.i. and plasma obtained as
described above to determine the fractions of non-
metabolized [18F]NS14490. The samples were centri-
fuged at 13,000 rpm for 2 min to obtain plasma. Eight
aliquots of 125 μL from each plasma sample were added
to 500 μL ice-cooled acetonitrile, shaken for 2 min,
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5,000 rpm for 2 min. The supernatants of each sample
series were combined and concentrated to approxi-
mately 100 μL for radio-TLC and radio-HPLC analyses
as described above. The extraction efficiency was moni-
tored relative to the total radioactivity in aliquots. Bi-
exponential fitting of the percentages of untransformed
parent in extracts was performed and used to correct
the input function of [18F]NS14490 for the presence of
metabolites.
Analysis of PET data
After correction for attenuation, scatter, decay and scanner-
specific dead time, the images were reconstructed by fil-
tered back projection using a 4.9-mm FWHM Hanning
filter into 40 frames of increasing length. A summed PET
image of the entire 240-min recording was calculated for
each animal and used for alignment with a T1-weighed
MR image of a 6-week-old farm-bred pig as described pre-
viously [29]. Dynamic time-activity curves (TACs) were
calculated for the following volumes of interest (VOIs):
frontal cortex, temporal lobe, parietal lobe, occipital lobe,
hippocampus, striatum (defined as mean radioactivity in
caudate and putamen), cerebellum, thalamus, middle cor-
tex, ventral cortex, midbrain, pons, colliculi, left carotid
artery, and circle of Willis. The radioactivity in all VOIs
was calculated as the mean radioactivity concentration
(Bq mL–1) for the left and right sides. To generate stan-
dardized uptake values (SUVs in g mL–1) the VOI TACs
(in kBq mL–1) were normalized to the injected dose and
corrected for animal weight (in kBq g–1).
To investigate the selectivity of α7 nAChR blockade in
the cerebral vessels, retrospective calculation of SUV in
the left carotid artery and circle of Willis was done using
data from a similar study performed with the α4β2-
specific radioligand 2-[18F]FA-85380 [26].
The kinetics of [18F]NS14490 in the brain was calcu-
lated for each 240-min TAC relative to the metabolite-
corrected arterial input using a Matlab-based in-house
program for a one-compartment model with the blood
volume fixed at 0.05 mL g−1. We thus obtained estimates
of the unidirectional blood-brain clearance (K1; mL g
−1
min−1) and the apparent washout rate from the brain
(k2″; min
−1), and their ratio, defined as the distribution
volume (VT″; mL cm
−3) and theoretically identical to
VT = K1/k2(1 + k3/k4) [30]. The regional binding potential
(BPND = (VT″region − VT″blocked)/VT″blocked) in the un-
blocked condition was calculated for each brain region
relative to the hippocampus in the blocked condition,
assumed to be a global surrogate for K1/k2, in the ab-
sence of specific binding. For cerebral vessels, the indi-
vidually blocked condition was used to calculate the
BPND. VT″ was also calculated by the method of Logan
et al. [31] for the unblocked and blocked conditionsusing the interval 30 and 120 min for the linearization.
The significance of reductions under blockade was
assessed by Student's t test (one-tailed, unpaired).
Parametric maps of distribution volume VT″ were cal-
culated for each animal investigated under baseline and
blocking conditions using the metabolite and free frac-
tion corrected arterial input function and the Logan ref-
erence tissue method as implemented in PMOD version
3.5 (PMOD technologies, Ltd., Zurich, Switzerland) as
described previously [25].
Results and discussion
The current study proposes that the new PET radioli-
gand [18F]NS14490 is suitable to specifically image α7
nAChR in the brain and cerebral vasculature of pigs.
This suggestion is derived from the following observa-
tions as specified below: the radioligand shows a distri-
bution pattern in piglet brain which is characteristic for
α7 nAChR, a highly significant correlation between spe-
cific binding in vitro and in vivo, a sufficient brain ex-
traction (approximately 30%), an SUV which can be
significantly decreased by the specific α7 nAChR ligand
NS6740 by 24% to 38%, and a NS6740-induced increase
in the clearance rate constant k2″ estimated by one-
tissue-compartment modelling of approximately 30%
which is consistent with blockade of a specific binding
component.
Automated radiosynthesis
The biological data presented below were obtained based
on manual and automated radiosynthesis of [18F]NS14490.
The manual radiosynthesis of [18F]NS14490 was described
recently [22] and is based on the development of the auto-
mated radiosynthesis for [18F]fluspidine [32]. The manual
synthesis started with 2.5 to 3 GBq, whereas activities as
high as 15 GBq were used for the automated radiosynth-
esis of [18F]NS14490. The procedure included the separ-
ation of [18F]fluoride from the irradiated [18O]H2O, the
azeotropic drying with Kryptofix K222, the radiofluorina-
tion of precursor 1 (see Figure 1), semi-preparative HPLC,
SPE for purification and solvent exchange, as well as man-
ual evaporation and final formulation of the radiotracer in
PBS containing 5% ethanol. The setup of vials and con-
tainers of the automatic module and a table showing
which vials were used and how they were filled, and which
cartridges were used are presented in Additional file 1.
Initially, semi-preparative HPLC and SPE were opti-
mized as described in the following: Figure 2 (left) shows
the semi-preparative isolation of the radiotracer on a
Multospher AQ column, as in the manual synthesis [22].
The peak width of the product (tr = 28 min) is rather
broad with the product fraction eluting for more than
5 min. Testing of a Reprosil AQ column shows a reten-
tion time of 40 min, despite a flow gradient from 2 to
Figure 1 Radiosynthesis of [18F]NS14490.
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matogram indicates co-elution of product with UV-
active substances. Separation with the Reprosil-Gold
(Figure 2 bottom) shows a rapid separation of the prod-
uct (tr = 17 min) with a narrow peak width, and eventu-
ally, this column was utilized in further radiosyntheses.
As previously mentioned for the manual synthesis
[22], acidic solvents are necessary for a sufficient desorp-
tion of the radiotracer. HR-X cartridges were chosen also
for the automated radiosynthesis because their stationary
phase provides better pH stability. Unfortunately, etha-
nol containing 2% acetic acid gave a low elution rate
for [18F]NS14490 (<50%) unless excessive volume wasFigure 2 Semi-preparative RP-HPLC for the isolation of [18F]NS14490
(left; 35% MeCN, 65% water, 12.5 mM ammonium acetate (NH4OAc), flow r
65% water, 12.5 mM NH4OAc, flow rate 2 to 3 mL min
−1) and a Reprosil-Go
rate 2 mL min−1).employed. Elution with acetonitrile containing 1.5% for-
mic acid was nearly quantitative, with 4% ± 3% (n = 7)
of activity remaining on the cartridges.
After optimisation, the labelling yield of the automated
radiosynthesis of [18F]NS14490 as determined with radio-
TLC was 73% ± 9% (n = 7), and the specific activity was
226 ± 68 GBq μmol−1 (corrected to the end of synthesis,
n = 6). The measured radiochemical purity of the prod-
uct (≥92%) was lower than that previously achieved after
manual synthesis (≥95%) [22]. This may be related to (I)
the acid sensitivity of the radiotracer as discussed previ-
ously [22], (II) the acidic solvent needed for a quantita-
tive elution from the cartridge and (III) the higherin a module system with different columns. Multospher column
ate 2.5 mL min−1), a Reprosil-Pur C18 AQ column (right; 35% MeCN,
ld column (bottom; 35% MeCN, 65% water, 20 mM NH4OAc, flow
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the manual synthesis [22]. Apparently, the longer evap-
oration time of the larger volume of the acidic solvent
promoted the degradation as the radiotracer was ex-
posed longer to the acidic milieu.
Before using in PET studies of pigs, the suitability of
the radiotracer was proven by in vitro autoradiography.
Brain slices from pigs were incubated with [18F]NS14490
and selected α7 nAChR inhibitors. The specific binding
estimated by in vitro autoradiography showed a highly
significant correlation (see Additional file 1) to the PET
estimate of specific binding (see below).
Plasma input function
[18F]NS14490 was used in dynamic PET studies in juven-
ile pigs. The plasma input functions under baseline and
blocking conditions are shown in Figure 3A. They were
corrected for the presence of radiolabelled metabolites
investigated in plasma samples taken at 4, 16, 30, 60 and
120 min p.i. On average, 89% ± 3% of the radioactivity
was extracted by plasma protein precipitation. Chroma-
tographic analysis showed a spectrum of four radiometa-
bolites (Figure 4, inset), all of them more hydrophilic
than [18F]NS14490. The absence of significant cranial
uptake suggests that [18F]NS14490 is not defluorinated
in the pig.
Under control conditions, [18F]NS14490 represented
39% and 33% of the total plasma radioactivity at 30 and
60 min p.i. (Figure 4), respectively; pre-treatment with
NS6740 was without significant effect on determined
metabolite fractions values. Therefore, bi-exponential fit-
ting of the percentages of untransformed [18F]NS14490
of all investigated animals was performed (Figure 4), and
the obtained empiric function was used to correct the
input function of [18F]NS14490 for the presence of
metabolites.
Comparison of the corrected input functions under
baseline and blocking conditions (Figure 3A) shows a
15% to 20% increase during the first minutes afterFigure 3 Time-activity curves obtained during PET experiments. (A) T
of the whole brain and hippocampus of individual piglets. Experiments we
inset). Values are means ± S.D.initiation of the NS6740 infusion (baseline = 1.32 ± 0.38
SUV, blocking = 1.60 ± 0.02 SUV at 2 min p.i.).
Dynamic PET data
The uptake of [18F]NS14490 in piglet brain was investi-
gated by PET. The initial tracer influx to the brain
attained an SUVmax of 0.54 ± 0.07 under the control and
of 0.60 ± 0.09 under blocking conditions within the first
minutes after injection (Figure 3B). Examples of time-
activity curves in the hippocampus and the whole brain
for a control animal and an animal treated with a block-
ing dose of NS6740 are shown in Figure 3B. At the end
of the study (between 210 and 240 min p.i.), blocking by
NS6740 reduced the SUV by 38% (hippocampus) and
24% (midbrain) in comparison to the controls (p < 0.05
in all regions except the midbrain).
Compartmental analysis indicated unidirectional clear-
ance (K1) of approximately 0.15 mL g
−1 min−1 through-
out the brain (Table 1) which suggests an extraction
fraction of approximately 30% for the untransformed
tracer in the blood, relative to the cerebral blood flow in
anaesthetized piglets [33]. The washout was likewise
rapid in the untreated piglets, with an apparent k2″ close
to 0.05 min−1; the total distribution volume (VT″) is thus
approximately 3.5 mL g−1 throughout the brain. The ad-
ministration of NS6740 did not change the magnitude of
K1. However, k2″ was increased significantly by NS6740
administration in most brain regions, propagating to a
non-significant reduction in the magnitude of VT″ by
25% to 50% (Table 1); the increase in k2″ is consistent
with blockade of a specific binding component, which
however could not be examined further, as a two-
compartment reversible binding model did not give
stable parameter estimates (data not shown).
We used the lowest telencephalic magnitude of VT″
estimated under blocking conditions (hippocampus;
2.6 mL g−1) as a global surrogate for VT″, i.e. the ratio
K1/k2, of [
18F]NS14490 in the absence of specific binding.
Relative to this, the apparent BPND ranges from moderatehe metabolite-corrected plasma samples. (B) Those from measurement
re performed under baseline (n = 4) and blocking conditions (n = 3,
Figure 4 Percentage of untransformed [18F]NS14490 in plasma
as a function of circulation time. The inset shows a representative
chromatogram of a plasma extract at 30 min p.i. The retention time
of [18F]NS14490 was 41 min. A total of four radiometabolites were
detected (M1 to M4).
Rötering et al. EJNMMI Research 2014, 4:43 Page 7 of 11
http://www.ejnmmires.com/content/4/1/430.2 in the cerebellum and midbrain to a maximum of
nearly 0.5 in the cerebral cortex (Table 1).
Furthermore, we observe evidence for a specific α7
nAChR binding component in the large arteries supply-
ing the brain. The SUV of [18F]NS14490 at the end of
the study was 36% and 24% reduced by treatment with
NS6740 in the carotid artery (p < 0.05) and in the circle
of Willis, respectively. Retrospective analysis of a similar
study performed with the α4β2-specific radioligand 2-Table 1 Kinetic parameters of the blood-brain partitioning of
Control (n = 4)a
K1 k2″ VT″
Frontal cortex 0.161 (0.055) 0.046 (0.003) 3.78 (1.01
Temporal cortex 0.145 (0.034) 0.040 (0.003) 3.98 (1.02
Parietal cortex 0.149 (0.037) 0.044 (0.001) 3.63 (0.86
Occipital cortex 0.171 (0.064) 0.051 (0.008) 3.59 (0.84
Basal forebrain 0.163 (0.035) 0.048 (0.006) 3.75 (0.74
Hippocampus 0.146 (0.044) 0.045 (0.005) 3.50 (0.68
Striatum 0.137 (0.029) 0.043 (0.004) 3.48 (0.80
Thalamus 0.160 (0.032) 0.049 (0.003) 3.54 (0.69
Midbrain tegmentum 0.161 (0.026) 0.053 (0.007) 3.47 (0.99
Colliculi 0.162 (0.035) 0.059 (0.003) 3.05 (0.71
Pons 0.205 (0.090) 0.066 (0.010) 3.33 (0.85
Cerebellum 0.186 (0.078) 0.061 (0.005) 3.15 (0.96
Full brain 0.170 (0.054) 0.050 (0.004) 3.56 (0.85
Carotid artery 0.406 (0.194) 0.059 (0.015) 6.71 (1.37
Circle of Willis 0.285 (0.136) 0.050 (0.012) 5.37 (1.35
Data are obtained from a one-tissue compartment model. Values are means ± S.D.; n.s
apparent washout rate constant from the brain (k2″; min
−1) and the total distribution v
the unblocked condition, we calculated the binding potential BPND relative to VT″ in th
*p < 0.001, **p < 0.005, ***p < 0.01.[18F]FA-85380 [26] did not reveal any alterations of SUV
under receptor blockade (control 0.604 ± 0.240, blocked
0.604 ± 0.124).
The effect of α7 nAChR blockade with NS6740 on the
uptake of [18F]NS14490 in the brain and brain vessels is
clearly seen on the parametric images of VT″ calculated
by Logan analysis (Figure 5). The VT″ values from the
Logan plots are highly correlated (r = 0.99) to the VT″
values from the compartmental analysis (see Additional
file 1).
Several lines of evidence show that α3, α4, α5, α7, α10,
β2, β3 and β4 nAChR subunits are expressed on human
vascular endothelial and smooth muscle cells and that
they mediate some of the deleterious effects of nicotine
in the vessels [34,35]. The homogeneous α7 nAChRs pri-
marily mediate endothelial cell proliferation, invasion
and angiogenesis. Nicotine induces the expression of
endothelial growth factors such as bFGF, PDGF-BB,
TGF-α and VEGF in the endothelial cells explaining the
pro-angiogenic nAChR-mediated effect of nicotine.
These growth factors are also overexpressed in atheros-
clerotic plaques [35,36]. Nicotine promotes atheros-
clerotic plaque neovascularization and may enhance
plaque vulnerability, since this critically depends on neo-
vascularization and changes in endothelial connexin ex-
pression [37]. Vascular smooth muscle cells particularly
express α3, α4, α5, α7 and α10 nAChR subunits. They
contribute to angiogenesis and the control of smooth
muscle cell proliferation [34]. Interestingly, some of the[18F]NS14490 in the brain and brain vasculature
Blocked (n = 3)a
BPND K1 k2″ VT″
) 0.45 0.163 (0.029) 0.059 (0.003)* 2.82 (0.62)
) 0.53 0.145 (0.028) 0.049 (0.001)** 3.04 (0.69)
) 0.40 0.155 (0.034) 0.056 (0.004)* 2.81 (0.61)
) 0.40 0.164 (0.045) 0.062 (0.005)*** 2.70 (0.59)
) 0.44 0.164 (0.040) 0.055 (0.002) n.s. 3.04 (0.72)
) 0.35 0.154 (0.035) 0.062 (0.010)*** 2.60 (0.61)
) 0.34 0.149 (0.038) 0.055 (0.001)** 2.76 (0.71)
) 0.35 0.177 (0.039) 0.065 (0.001)* 2.78 (0.68)
) 0.33 0.159 (0.034) 0.062 (0.004) n.s. 2.59 (0.61)
) 0.17 0.178 (0.042) 0.071 (0.006)** 2.53 (0.50)
) 0.28 0.201 (0.034) 0.077 (0.011) n.s. 2.72 (0.84)
) 0.21 0.193 (0.064) 0.070 (0.003)*** 2.80 (0.96)
) 0.37 0.166 (0.032) 0.059 (0.001)** 2.78 (0.66)
) 0.18 0.367 (0.095) 0.064 (0.002) n.s. 5.71 (1.37)
) 0.11 0.254 (0.132) 0.051 (0.021) n.s. 4.83 (0.86)
., not significant. aThe unidirectional blood-brain clearance (K1; mL g
−1 min−1), the
olume (VT″; mL g
−1) were calculated with plasma volume fixed at 0.025 mL g−1. In
e blocked condition. Significant difference between k2″ in the two groups:
Figure 5 Parametric maps of the distribution volume (VT) of
[18F]NS14490 in the brain of piglets. Experiments were carried
out under control (unblocked) conditions and with pre-treatment with
the competitor NS6740 (blocked). Parametric maps are projected onto
an MR atlas for the pig brain and represent the mean of (n = 4) control
animals and (n = 3) animals with blocking. Data are given in mL g−1.
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at concentrations equivalent to plasma levels observed
in only moderate smokers [36].
At the time of first publication, [18F]NS14490 showed
so far the highest α7 nAChR affinity (2.5 nM) among the
published 1,4-diazabicyclo[3.2.2]nonane derivatives in
addition with 40- and 400-fold selectivity towards human
α3β4 and α4β2 nAChR, respectively [14,22]. Accordingly,
an automated radiosynthesis has been developed for fur-
ther preclinical PET studies in pigs. After the described
optimisation, the labelling yield of the automated radio-
synthesis (73% ± 9%; n = 7) as determined with radio-TLC
was identical to that of the manual synthesis (71% ± 9%;
n = 12) [22]. The radiochemical yield (35% ± 4%) was
comparable to that for the previously published radio-
chemical automatic synthesis of [18F]fluspidine [32] the
module parameters of which were used as template for
the current procedure.
Regarding metabolic stability, species-specific differ-
ences were observed with a faster metabolism of [18F]
NS14490 in piglets than in mice (at 60 min p.i. [18F]
NS14490 accounts for 33% and 56% of plasma activity,
respectively) [22]. In pig plasma, chromatographic ana-
lysis showed a spectrum of radiometabolites similar to
that seen in mouse plasma. Since metabolite M4 (Figure 4),
eluting just prior to the parent compound and detected at
comparable levels in both mouse and pig, was nearly ab-
sent in mouse brain [22], it is unlikely that M4 penetrates
into the pig brain in the present study.
Very recently, the novel 1,4-diazabicyclo[3.2.2]nonane
derivative [18F]ASEM has been reported possessing an
eightfold higher affinity than NS14490 [19]. Accordingly,the distribution volumes VT of [
18F]ASEM in monkey
brain were about sixfold higher than the VT values of
[18F]NS14490 in the pig brain as calculated in this study.
Differently from our study, the α7 nAChR-selective par-
tial agonist SSR180711 [38] has been used for displace-
ment, and administration of 5 mg kg–1 blocked about
80% of [18F]ASEM binding in baboon brain [19].
Using NS6740 as α7 nAChR-selective inhibitor, we ob-
served a decrease of VT of [
18F]NS14490 in pigs which
was caused by an increase in k2″. This result indicates
NS6740-mediated blockade of a specific binding compo-
nent. However, this could not be examined further, as a
two-compartment reversible binding model did not give
stable parameter estimates. An alternative explanation
for the observed increase of k2″ could be an increased
washout of tracer due to cerebral blood flow effects of
NS6740 as was reported for the PET imaging of D3 re-
ceptors under antagonistic blockade [39]. However, this
is unlikely to be an issue in the herein investigated
NS6740-[18F]NS14490 approach, since the washout rate
was differently affected in the different brain regions.
Corresponding estimates of VT″ by the linearization of
Logan were 10% ± 2% higher than those by compartmen-
tal analysis (see Additional file 1). Since this bias was
similar in the blocked and unblocked conditions, thus
having no significant influence on the calculation of spe-
cific binding, the source of the methodology-related dif-
ferences in estimates of VT″ has not been investigated
further.
The relative changes in k2″ of [
18F]NS14490 by NS6740
with the largest effects observed in the hippocampus
(−35%) and the lowest reduction measured in the cerebel-
lum (−14%) correlate well (r = 0.66) with the density and
pattern of α7 nAChR binding sites detected by receptor
autoradiography in piglet brain [9]. The BPND values cal-
culated from the VT″ values estimated for control and
blocking conditions (region-specific between 0.17 and
0.45) are somewhat less than those determined for [18F]
NS10743 (between 0.24 and 0.76) and [11C]NS14492 (be-
tween 0.4 and 0.8) in porcine brain [20,25]. Interestingly,
the BPND values in the same range have been proven suit-
able to differentiate between healthy controls and patients
with Alzheimer's disease with regard to the availability of
α4β2 nAChR [40]. The average nonspecific binding, VND,
of [18F]NS14490 in the piglet brain as determined by the
occupancy plot (data in Additional file 1) was 2.2 mL cm−3
and thus accounts for almost 50% of the VT″ in regions
with high binding site densities, comparable to the ratio of
specific-to-nonspecific binding obtained with [11C]NS14492
in pig [20] as well as other PET tracers in the human
brain, for example 2-[18F]FA-85380 [40]. The parametric
maps of VT″ of [
18F]NS14490 in the control and blocked
conditions corroborate the finding of rather diffuse spe-
cific binding in the brain (Figure 5). The low apparent
Rötering et al. EJNMMI Research 2014, 4:43 Page 9 of 11
http://www.ejnmmires.com/content/4/1/43displacement may in part be due to the low spatial reso-
lution of the clinically applied but herein preclinically used
PET instrumentation, which likely results in considerable
loss of signal from small structures in particular in the pig
brain. However, the relatively weak displacement effect is
largely an inherent problem in the detection of α7 nAChR
caused by the comparably low expression of the α7
nAChR protein. Receptor autoradiography in pig brain re-
vealed a maximum density of only 12 pmol g−1 [9], as
compared to 120 pmol g−1 for dopamine D2/3 receptors in
pig caudate [41]. Accordingly, also, the BPND values calcu-
lated from [18F]ASEM PET studies in baboons differ only
about 40% between low- and high-binding regions [19]
which is even less than the difference found in the herein
presented PET study (approximately 70%).
In addition to the specific binding of [18F]NS14490 in
the brain, our data prove an α7 nAChR specific binding
component of [18F]NS14490 in the large arteries supply-
ing the brain. The BPND values of 0.18 and 0.11 were
calculated in the carotid artery and in the circle of
Willis, respectively. This result is consistent with an
early observation on α-bungarotoxin binding sites in the
carotid body [42], the known presence of α7 nAChR on
brain and peripheral endothelial cells [43,44], the modu-
lation of porcine basilar arteries by presynaptic α7
nAChRs in sympathetic terminals [45] and may, in the
context of atherosclerosis, be relevant to an α7 nAChRs-
mediated release of inflammatory cytokine by macro-
phages [46].
Interestingly, the sagittal views of the VT″ images of
[18F]ASEM in baboons show extracerebral structures
with clear inhibition of VT″ after the administration of
SSR180711, which might be identical to brain vessels
[19]. Such result would support our suggestion that α7
nAChR PET radioligands may be suitable to investigate
brain vessel diseases in human.
Conclusions
In conclusion, the present study demonstrated that [18F]
NS14490 could be used to specifically assess the availabil-
ity of α7 nAChR in brain structures as well as in the large
arteries supplying the brain. An assumed potential of [18F]
NS14490 to detect α7 nAChR in vulnerable plaques of
diseased vessels will be investigated in further studies.
Additional file
Additional file 1: Imaging of α7 nicotinic acetylcholine receptors in
brain and cerebral vasculature of juvenile pigs with [18F]NS14490.
The supplemental material provides more detailed information on the
radiosynthesis of [18F]NS14490 including the experimental setup and the
mode of action. The procedure of the in vitro autoradiography is
described there. It furthermore contains additional information on the
results of the in vitro autoradiography and the dynamic PET studies in the
brain of piglets.Abbreviations
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